Cargando…
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
BACKGROUND: Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer. Enoxaparin, a low molecular weight heparin (LMWH), has proven to be effective for the prevention and tre...
Autores principales: | Riess, Hanno, Pelzer, Uwe, Hilbig, Andreas, Stieler, Jens, Opitz, Bernhard, Scholten, Theo, Kauschat-Brüning, Dörte, Bramlage, Peter, Dörken, Bernd, Oettle, Helmut |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613915/ https://www.ncbi.nlm.nih.gov/pubmed/19055847 http://dx.doi.org/10.1186/1471-2407-8-361 |
Ejemplares similares
-
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer – the CONKO 004 pilot trial
por: Pelzer, Uwe, et al.
Publicado: (2014) -
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
por: Sinn, M, et al.
Publicado: (2014) -
Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation
por: Striefler, Jana K., et al.
Publicado: (2022) -
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
por: Striefler, Jana Käthe, et al.
Publicado: (2021) -
Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy
por: Pelzer, Uwe, et al.
Publicado: (2013)